Market Spotlight:  Thyroid Cancer

 

Disease Overview

This Market Spotlight report covers the Thyroid cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2016 there were 312,000 incident cases of thyroid cancer worldwide, and forecasts that number to increase to 342,000 incident cases by 2025.

Asia is estimated to have the highest disease incidence, while Oceania has the lowest incidence. The approved drugs in the thyroid cancer space focus on a variety of targets. These drugs are commonly administered via the oral route, with one product being available in intramuscular formulation.

A majority of industry-sponsored drugs in active clinical development for thyroid cancer are in Phase II, with only one drug in Phase III.

Therapies in mid-to-late-stage development for thyroid cancer focus on targets such as mitogen-activated ERK kinase, microtubules (tubulin), carcinoembryonic antigen, Raf kinase, tumor necrosis factor-alpha, RET, and ErbB3/HER3. The majority of the drugs in mid-to-late-stage development for thyroid cancer are administered via the oral route, with the remainder being intravenous or subcutaneous.

High-impact upcoming events for drugs in the thyroid cancer space include topline Phase II and Phase III trial results. There were 10 licensing and asset acquisition activities involving thyroid cancer drugs during 2012–17. The largest deal during that time was the $1,119.0m exclusive licensing agreement in February 2016 between Exelixis and Ipsen, for the commercialization and further development of Cometriq (cabozantinib).

Nexavar’s sales ranked highest among drugs available for thyroid cancer during 2012–16, and revenues are expected to remain high until 2019.

The clinical trials distribution across Phase I–IV indicates that the majority of trials for thyroid cancer have been in early and midphases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.

The US has a substantial lead in the number of thyroid cancer clinical trials globally. France leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the thyroid cancer space is dominated by completed trials. Pfizer, GlaxoSmithKline, and AstraZeneca have the highest number of completed clinical trials for thyroid cancer, with 25, 22, and 20 completed trials, respectively.

Novartis leads industry sponsors with the highest number of clinical trials for thyroid cancer, followed by Pfizer and GlaxoSmithKline.

 

Exclusive Sample Report @ https://www.reportsworldwide.com/enquiry?report_id=42612

Major TOC Market:

1 KEY TAKEAWAYS

2 DISEASE BACKGROUND
3 Thyroid cancer subtypes
4 TREATMENT
5 Surgery
6 Radioactive iodine (RAI) therapy
7 Thyroid hormone therapy
8 External-beam radiation therapy
9 Targeted therapy

10 EPIDEMIOLOGY

11 MARKETED DRUGS

12 PIPELINE DRUGS

13 KEY UPCOMING EVENTS

14 LICENSING AND ASSET ACQUISITION DEALS
15 Takeda Adds Exelixis Arrow To Oncology Quiver

16 PARENT PATENTS

17 REVENUE OPPORTUNITY

18 CLINICAL TRIAL LANDSCAPE
19 Sponsors by status
20 Sponsors by phase

21 BIBLIOGRAPHY
22 Prescription information

23 APPENDIX

LIST OF FIGURES
 Figure 1: Trends in incident cases of thyroid cancer, 2016–25
Figure 2: Pipeline drugs for thyroid cancer in the US
Figure 3: Pipeline drugs for thyroid cancer, by company
Figure 4: Pipeline drugs for thyroid cancer, by drug type
Figure 5: Pipeline drugs for thyroid cancer, by classifications
Figure 6: Key upcoming events in thyroid cancer
 Figure 7: Licensing and asset acquisition deals in thyroid cancer
 Figure 8: Parent patents in thyroid cancer
 Figure 9: Clinical trials in thyroid cancer
 Figure 10: Top 10 drugs for clinical trials in thyroid cancer
 Figure 11: Top 10 companies for clinical trials in thyroid cancer
 Figure 12: Trial locations in thyroid cancer
Figure 13: Thyroid cancer sponsors, by status
Figure 14: Thyroid cancer sponsors, by phase

LIST OF TABLES
Table 1: Incident cases of thyroid cancer, 2016–25
Table 2: Marketed drugs for thyroid cancer
Table 3: Approvals by country for thyroid cancer
Table 4: Pipeline drugs for thyroid cancer in the US
Table 5: Historical global sales, by drug ($m), 2012–16
Table 6: Forecasted global sales, by drug ($m), 2017–22

Ask to Expertise @ https://www.reportsworldwide.com/enquiry?report_id=42612  

About US:

Reportsworldwide.com is a one stop shop for all market intelligence needs. Our database of market research reports provides in depth coverage of 12 top industry verticals worldwide. We help you meet your market intelligence needs by mapping it with our database of market research reports including.

Contact Us:

Email: sales@reportsworldwide.com

Phone: +1 (617) 398-1947